January 14, 2026

Whole-Genome Sequencing–Based Classifier Better Predicts Homologous Recombination Deficiency Across Cancer Types

A whole-genome sequencing–based classifier demonstrated greater performance for predicting homologous recombination deficiency across cancer types than standard assays, which in turn determined which ...

The ASCO Post

October 13, 2025

Women With Gynecologic Cancers More Likely to Leave The Workforce

Older age, lower income, and depression increased resignation risk across all cancer cohorts.

Conexiant

September 11, 2025

Treatment of Anal Precancer May Lower Cancer Risk in HIV

Routine screening now includes anoscopy to confirm positive anal Pap or HPV test results.

Conexiant

March 25, 2025

2023–2024 Drug Updates in Solid Tumors

Jadpro

March 25, 2025

2023–2024 Drug Updates in Solid Tumors

Jadpro

December 09, 2024

NCCN Joins International Cancer Organizations During Oncology Event in China

The National Comprehensive Cancer Network (NCCN) took part in the 2024 International Congress of the Asian Oncology Society and the 2024 Chinese Congress on Holistic Integrative Oncology. This event h...

The ASCO Post

December 04, 2024

Lenvatinib/Pembrolizumab vs Chemotherapy in Advanced Endometrial Cancer

As reported in Journal of Clinical Oncology by Marth et al, the phase III European Network of Gynaecological Oncological Trial-en9/LEAP-001 study evaluated the impact of first-line lenvatinib/pembroli...

The ASCO Post

December 04, 2024

Lenvatinib/Pembrolizumab vs Chemotherapy in Advanced Endometrial Cancer

As reported in Journal of Clinical Oncology by Marth et al, the phase III European Network of Gynaecological Oncological Trial-en9/LEAP-001 study evaluated the impact of first-line lenvatinib/pembroli...

The ASCO Post

October 09, 2024

KEYNOTE-A18: Overall Survival in Cervical Cancer Improved by Pembrolizumab Plus Chemoradiotherapy

The phase III KEYNOTE-A18 trial, presented at the European Society for Medical Oncology (ESMO) Congress 2024, found that treatment with the PD-1 inhibitor pembrolizumab plus chemoradiotherapy, with pe...

The ASCO Post

October 09, 2024

KEYNOTE-A18: Overall Survival in Cervical Cancer Improved by Pembrolizumab Plus Chemoradiotherapy

The phase III KEYNOTE-A18 trial, presented at the European Society for Medical Oncology (ESMO) Congress 2024, found that treatment with the PD-1 inhibitor pembrolizumab plus chemoradiotherapy, with pe...

The ASCO Post